An Open-Label, Non-randomized, Prospective Biomarker Study to Assess Analytic Concordance Between Non-invasive Testing and Tissue Testing for EGFR T790M Mutation Detection in Patients With Non-small Cell Lung Cancer
Not yet recruiting
Phase of Trial: Phase IV
Latest Information Update: 06 Oct 2017
At a glance
- Drugs Osimertinib (Primary)
- Indications Non-small cell lung cancer
- Focus Biomarker; Diagnostic use
- Acronyms RADIANCE
- Sponsors AstraZeneca
- 29 Sep 2017 Planned End Date changed from 23 Apr 2020 to 28 Sep 2020.
- 29 Sep 2017 Planned primary completion date changed from 23 Apr 2020 to 28 Sep 2020.
- 29 Sep 2017 Planned initiation date changed from 16 May 2017 to 9 Oct 2017.